Skip to main content

Table 1 Distribution of the responses in the 28-day trial

From: Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

Year

Treatment

Number included

Parasite clearance on day 3 (ITT) (%)

Observed ACPR

Lost to follow-up and excluded

Reinfection

ITT1

PP1

2005

AQ

64

87.5

50

5

5

50/64

(55/64)

50/59

(55/59)

 

AS-AQ

60

100

43

6

10

43/60

(53/60)

43/54

(53/54)

 

AS-SP

61

96.8

50

4

4

50/61

(54/61)

50/57

(54/57)

2006a

AQ-SP

67

86.6

55

5

7

55/67

(62/67)

55/62

(62/62)

 

AS-MQ

69

95.7

60

8

1

60/69

(61/69)

60/61

(61/61)

2006b

AS-AQ

62

98.4

52

5

3

52/62

(55/62)

52/57

(55/57)

 

AM-LM

61

100

58

1

2

58/61

(60/61)

58/60

(60/60)

2006c

AS-CD

83

97.6

53

12

7

53/83

(60/83)

53/71

(60/71)

 

AS-SP

85

100

73

6

1

73/85

(74/85)

73/79

(74/79)

2007

AS-AQ

92

99

73

4

8

73/92

(81/92)

73/88

(81/88)

 

DH-PP

91

100

84

5

0

84/91

(84/91)

84/86

(84/86)

  1. 1Values in parentheses denote the observed proportions of ACPR after PCR correction in each treatment group. No recrudescence was observed with the AM-LM combination, and no re-infection was observed with DH-PP. ITT, intention-to-treat; PP, per protocol.